The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians because of its frequency and the severity of adverse events related to it. The identification of patients with high platelet reactivity (HPR may help to improve their therapy applying the concept of personalized medicine, most important in the older people treated with polypharmacy. The existece of such a simple clinical method as the STIB score, that allows to predict the possible resistace to clopidogrel at the bedside without using expensive laboratory investigations, provides an attractive approach to the problem.

Gallotta, A., Marengoni, A., Pasina, L., Cortesi, L., Nobili, A., Barbagallo, M., et al. (2017). Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 41, e17-e18 [10.1016/j.ejim.2017.03.024].

Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry

Barbagallo, Mario;Dominguez Rodríguez, Ligia Juliana
2017-01-01

Abstract

The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians because of its frequency and the severity of adverse events related to it. The identification of patients with high platelet reactivity (HPR may help to improve their therapy applying the concept of personalized medicine, most important in the older people treated with polypharmacy. The existece of such a simple clinical method as the STIB score, that allows to predict the possible resistace to clopidogrel at the bedside without using expensive laboratory investigations, provides an attractive approach to the problem.
Settore MED/09 - Medicina Interna
Gallotta, A., Marengoni, A., Pasina, L., Cortesi, L., Nobili, A., Barbagallo, M., et al. (2017). Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 41, e17-e18 [10.1016/j.ejim.2017.03.024].
File in questo prodotto:
File Dimensione Formato  
letter prevalence clopidogrel 2017.pdf

Solo gestori archvio

Dimensione 334.66 kB
Formato Adobe PDF
334.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/400035
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact